Extracorporeal Photopheresis after Solid-Organ Transplant and for Graft-versus-Host Disease, Autoimmune Disease, and Cutaneous T-Cell Lymphoma

Extracorporeal Photopheresis after Solid-Organ Transplant and for Graft- versus-Host Disease, Autoimmune Disease and Cutaneous T-Cell Lymphoma

The standard of care for treatment of organ transplant rejection is immunosuppression, with the particular regimen dictated by the organ being transplanted. As organ transplantation success rates have improved, more patients are facing the morbidity and mortality associated with immunosuppressive therapies developed to prevent rejection of the transplanted organ. Immunosuppressive therapies are...

The role of extracorporeal photopheresis in the management of cutaneous T‐cell lymphoma, graft‐versus‐host disease and organ transplant rejection: a consensus statement update from the UK Photopheresis Society

Extracorporeal photopheresis (ECP) has been used for over 35 years in the treatment of erythrodermic cutaneous T-cell lymphoma (CTCL) and over 20 years for chronic and acute graft-versus-host disease (GvHD) and solid organ transplant rejection. ECP for CTCL and GvHD is available at specialised centres across the UK. The lack of prospective randomised trials in ECP led to the development of UK C...

Extracorporeal Photopheresis as a Treatment of Graft-versus-Host Disease, Autoimmune Disease and Cutaneous T-Cell Lymphoma

Extracorporeal photopheresis: how, when, and why.

Extracorporeal photopheresis (ECP) is a well-tolerated procedure that suppresses T-lymphocyte activity in a clonally-specific way. It is an effective therapy that has established indications in the management of cutaneous T-cell lymphoma, graft-versus-host disease and some scenarios of solid-organ transplant rejection. It is being used increasingly around the world. Its applications are evolvin...

Guidelines on the use of extracorporeal photopheresis

BACKGROUND After the first investigational study on the use of extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma was published in 1983 with its subsequent recognition by the FDA for its refractory forms, the technology has shown significant promise in the treatment of other severe and refractory conditions in a multi-disciplinary setting. Among the major studied condit...